

# Patient Dosimetry in SPECT/CT Lymphoscintigraphy Examinations

Abdullah Almujaally<sup>1\*</sup>, Abdelmoneim Sulieman<sup>2</sup>, Hassan Salah<sup>3</sup>, Bander A Ianazi<sup>4</sup>,  
Fabrizio Calliada<sup>1</sup>

<sup>1</sup>Radiology Institute, University of Pavia, Italy

<sup>2</sup>Radiology and Medical Imaging Department, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, P.O.Box 422, Alkharj 11942, Saudi Arabia

<sup>3</sup>Nuclear Medicine Department, INAYA Medical Collage, Riyadh 13541, Saudi Arabia

<sup>4</sup>Department of Radiology, King Khalid Hospital, Ministry of Health, Hail, Saudi Arabia

## ABSTRACT

**Background:** Lymphoscintigraphy imaging procedure is performed at the nuclear medicine department to evaluate sentinel lymph nodes for excisional biopsy in patients with melanoma, and to assess the use of the intraoperative gamma probe in the operating room. The objectives of this study are to evaluate the radiation dose of patients during lymphoscintigraphy SPECT/CT procedure and to estimate its radiogenic risk.

**Methods:** Of the thirty patients that underwent SPECT/CT in this research, 63.3 % (19 patients) and 36.7 % (11 patients) were females and males, respectively. For SPECT/CT [GE Hualun Medical Systems (Discovery NM/CT 670Pro)].

**Results:** The effective dose (mSv) per procedure ranges from 0.21 to 0.5 mSv, with an average dose value of 0.22 mSv. The effective dose for CT examination is 0.05 (ranging from 0.04 to 0.1 mSv per procedure). Therefore, the effective dose for CT is lower than that for SPECT by a factor of 5. This radiation risk is equivalent to 5 weeks of natural background radiation exposure.

**Conclusions:** The level of radiation dose place it under the category of low radiation risk for cancer, equivalent to 1 cancer case per 10<sup>5</sup> SPECT/CT lymphoscintigraphy procedures. Moreover, this dose is lower than previously published studies suggesting that the patients were well protected during the entire procedure.

**Key words:** Effective dose, SPECT/CT, Lymoscintigraphy, Radiation risk

**HOW TO CITE THIS ARTICLE:** Abdullah Almujaally, Abdelmoneim Sulieman, Hassan Salah, Bamdar Alanazi, Fabrizio Calliada, Patient Dosimetry in SPECT/CT Lymphoscintigraphy Examinations, J Res Med Dent Sci, 2020, 8(5): 97-100.

**Corresponding author:** Abdullah Almujaally  
**e-mail:** abdullah.almujaally@gmail.com  
**Received:** 05/08/2020  
**Accepted:** 20/08/2020

## INTRODUCTION

Lymphoscintigraphy imaging procedure is performed at the nuclear medicine department to evaluate sentinel lymph nodes for excisional biopsy in patients with melanoma, and to assess the use of the intraoperative gamma probe in the operating room. Patients with lymphedema are exposed to repetitive radiation exposures from hybrid and separated CT and nuclear medicine examinations. Lymphatic-edema or lymphedema is an acute debilitating disease that is often wrongly diagnosed, cured too late, or not treated at all. Lymphoma results from reduced lymphatic transport because of injury to the lymphatics, infection, or congenital abnormality [1-3]. Patients with lymphatic disease may not present with pain in mild conditions. Lymphoscintigraphy is an effective

therapeutic means of diagnosing lymphatic-edema, and it can be applied mostly after the disease has been categorized. The number of cases of secondary lymphedema (breast and pelvic cancer therapy, frequent infections, injuries, or vascular surgery) is about 10 million, and the worldwide incidence of parasitic infections is about 90 million [1-3].

To effectively treat lymphedema, lymphoscintigraphy is used to understand its pathophysiology and the influence of technical factors like the choice of radiotracer, the time of injection, and the patient's activity after injection on the images [4-7].

Lymphoscintigraphy is also used to evaluate breast cancer-related lymphedema (BCRL). The procedure distinguishes normal lymphatic function from lymphedema. The perfect radiotracer for the study of the lymphatic system is one that enters the lymphatic system without any clearance through the microvascular blood circulation. <sup>99m</sup>Tc labelled with human serum albumin (HSA) shows this



and patients' and staff's safety. Patient's data included age, body mass index (BMI(kg/m<sup>2</sup>)), duration of lymphedema, location of disease, gender, and clinical indications. The effective doses (E) were estimated using the OLINDA software (Vanderbilt University, Nashville, USA), while the effective dose from CT was estimated using the Impact software (Saint George Hospital, London, UK).

**RESULTS AND DISCUSSION**

Table 2 shows the administered radiopharmaceuticals for patients during lymphoscintigraphy using a hybrid system (SPECT/CT) according to the King Fahad Medical City (KFMC) imaging protocol. The effective radiation doses during SPECT/CT lymphoscintigraphy depend on exposure parameters for the CT machines and the amount of the administered activities. Of the thirty patients that underwent SPECT/CT in this research, 63.3% (19) and 36.7% (11) were females and males, respectively. Table 2 presents patients' characteristics

(age (y), and height (m)) and the administered activity per patient. The effective dose (mSv) per procedure ranged from 0.19 to 0.41 mSv, with an average dose value of 0.22 mSv. There was no variation between administered activity and patient's effective doses according to the gender. During CT examination as a part of the SPECT/CT procedure, patients received higher doses compared to the effective doses gotten from the administration of <sup>99m</sup>Tc sulfur colloid. The average effective dose obtained from CT examination was 0.05, ranging from 0.04 to 0.1 mSv per procedure. The effective dose in CT was therefore lower than that of the SPECT procedure by a factor of 5. This was attributed to the low radiosensitivity of the lower limbs because no sensitive organs are included in the primary beam. During SPECT/CT lymphoscintigraphy examinations, the radiation dose is low compared to other SPECT/CT imaging procedures or even during separate SPECT or CT procedures. This low dose is due to the small amount of administered activity and low exposure parameters.

**Table 2: Mean, standard deviation and range of patient's demographic data and administered activity.**

Gender	No	Age (y)	Height (cm)	Weight (kg)	Activity (mCi)	Activity (MBq)	Effective dose (mSv)
F	19	45.05 ± 16 (12-75)	154.79 ± 6 (144-162)	92 ± 25 (46-145)	0.56 ± 0.2 (0.5-1.1)	21 ± 6 (18.5- 40.7)	0.21 ± 0.01 (0.19-0.41)
M	11	40 ± 17 (12- 57)	168 ± 19 (132-181)	(105 ± 22) (61-121)	0.58 ± 0.2 (0.51.0)	21.6 ± 8 (18.5- 37)	0.22 ± 0.01 (0.19-0.4)
Overall	30	44 ± 16 (12-75)	158 ± 11 (132-181)	(95 ± 25) (46-145)	0.57 ± 0.2 (0.5-1.1)	21 ± 7 (18.5-40.7)	0.21 ± 0.01 (0.19-0.41)

From Table 3, the CT imaging protocol is based on fixed exposure parameters. The effective dose (mSv) conversion factor from DLP (mGy.cm) is comparable with the value reported by others (0.0002 mSv/DLP (mGy.cm)). The overall patient radiation dose of SPECT/CT is the summation of the effective dose due to the radiopharmaceutical material injected (<sup>99m</sup>Tc sulfur

colloid) for SPECT image acquisition and the effective CT dose resulting from external radiation exposure. Therefore, careful radiation dose optimization during SPECT/CT procedures will reduce the patient doses to the lowest possible level without affecting the clinical findings [13].

**Table 3: CT exposure parameters and patients' doses during SPECT/CT examination.**

Tube potential (kVp)	Tube current –time product (mAs)	rotation time (s)	slice thickness(mm)	pitch	CTDIvol (mGy)	DLP (mGy.cm)	Effective dose (mSv)
120	80	0.8	3.75	1.375	4.11	241.4 ± 74 (178.8-324.1)	0.05 ± 0.01 (0.04-0.1)

For this reason, the radiopharmaceutical material used and its administered activity, as well as the image acquisition and processing modalities both in SPECT and in CT must be carefully evaluated. The use of SPECT/CT lymphoscintigraphy procedures in clinical practice is important due to its ability to demonstrate the lymphatic vessel drainage patterns. Therefore, with a low dose per procedure, the surgeon can use the imaging without any increase in radiation risk. The current radiation risk from SPECT/CT is equivalent to 5 weeks of natural background radiation exposure. This places it under the category of low radiation risk for cancer, equivalent to 1 cancer case per 10<sup>5</sup> SPECT/CT lymphoscintigraphy procedures.

Buck et al. [14] showed that the effective dose of SPECT/CT ranged from 0.19 to 0.41 mSv using low dose

imaging protocol per procedure, which is higher than the current study. However, Roach et al. [15] reported comparable values to our study, ranging from 1–2 mSv per SPECT/CT procedure. In addition, patients' effective doses (mSv) per SPECT/CT for chest, abdominopelvic, and head were reported to be 1.1, 1.3, and 0.2 mSv respectively [16]. The CT dose during SPECT/CT is within the diagnostic reference level values range that proposed by Avramova-Cholakova et al. [17] (CTDIvol=4 mGy, DLP (mGy.cm)=120 and administered activity (MBq)=74).

**CONCLUSIONS**

In the current study, the patients' doses during SPECT/CT lymphoscintigraphy were evaluated. The patients' radiation dose from the administered activity was higher than the effective dose obtained from CT by a factor of 22.

